New combo therapy offers hope for Drug-Resistant digestive cancer
NCT ID NCT07559864
First seen May 02, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tests whether combining two drugs—regorafenib and envafolimab—can help people with a rare type of stomach or intestinal cancer (GIST) that has stopped responding to standard treatments. About 100 adults with a specific gene mutation (KIT exon 17) will be randomly assigned to receive either the combination or the doctor's choice of other therapies. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST - GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100101, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.